Compounding Pharmacy Peptides

Overview

Compounding pharmacies have become a significant source of peptide therapeutics, particularly in the United States. These pharmacies prepare customized medications by combining, mixing, or altering ingredients to create formulations tailored to individual patient needs — a practice known as pharmaceutical compounding.

The role of compounding pharmacies in the peptide space has expanded dramatically, driven by two forces: growing clinical interest in peptides that are not commercially available as approved drugs, and supply shortages of approved peptide medications (most notably GLP-1 receptor agonists). This expansion has brought increased regulatory scrutiny and a rapidly evolving legal landscape.

Understanding the distinction between different types of compounding facilities, the regulatory framework governing them, and the quality considerations specific to compounded peptides is essential for anyone interacting with this sector.

What Is Pharmaceutical Compounding?

Pharmaceutical compounding is the practice of creating personalized medications that are not commercially available in the needed form, strength, or combination. Historically, compounding was a core pharmacy function — before mass pharmaceutical manufacturing, virtually all medications were compounded.

Modern compounding serves several legitimate needs:

• Dose customization: Preparing specific doses not available in commercial products (e.g., pediatric doses, titration doses)
• Alternative delivery forms: Converting an oral medication to a topical cream, suppository, or injectable formulation
• Allergen-free formulations: Removing dyes, preservatives, or other excipients that a patient cannot tolerate
• Discontinued or unavailable medications: Preparing drugs that manufacturers have stopped producing
• Combination products: Combining multiple active ingredients into a single preparation for convenience

In the peptide context, compounding pharmacies prepare injectable peptide solutions from bulk peptide powder (Active Pharmaceutical Ingredient, or API), typically dispensed in sterile vials ready for subcutaneous injection.

The 503A and 503B Distinction

The Federal Food, Drug, and Cosmetic Act (as amended by the Drug Quality and Security Act of 2013) established two categories of compounding facilities:

503A Compounding Pharmacies

These are traditional compounding pharmacies that operate under Section 503A:

• Prescription required: Must compound based on a valid, individual patient prescription
• Licensed pharmacist: Must be operated by or under the direct supervision of a licensed pharmacist
• State regulation: Primarily regulated by state boards of pharmacy, with FDA oversight limited to specific circumstances
• Scale limitations: Cannot compound in anticipation of receiving prescriptions (no batch production for stock)
• Patient-practitioner relationship: A prescriber-patient relationship must exist
• USP standards: Must comply with United States Pharmacopeia (USP) compounding standards, including USP <797> for sterile preparations

503B Outsourcing Facilities

Created by the Drug Quality and Security Act of 2013 following the 2012 New England Compounding Center (NECC) meningitis outbreak that killed 76 people:

• FDA registered: Must register with the FDA as an outsourcing facility
• No individual prescription required: Can compound without patient-specific prescriptions (batch production)
• cGMP compliance: Must follow current Good Manufacturing Practice (cGMP) regulations — the same manufacturing quality standards applied to pharmaceutical manufacturers
• FDA inspection: Subject to FDA inspection on a risk-based schedule
• Adverse event reporting: Required to report adverse events to the FDA
• Labeling requirements: Must include specific labeling information, including a statement that the product is compounded

Key Differences Summary

FDA Category 1/2/3 System

In recent years, the FDA has implemented a categorization system for bulk drug substances (the raw active ingredients) used in compounding. This system determines which compounds compounding pharmacies may legally use:

Category 1: Permitted for Compounding

Bulk drug substances in Category 1 have been evaluated by the FDA and determined to be appropriate for use in compounding. These substances have adequate safety and characterization data. Compounding pharmacies (both 503A and 503B) may use Category 1 substances, subject to their respective regulatory requirements.

Category 2: Under Evaluation

Category 2 substances are currently being evaluated by the FDA. Their status is pending, and they may eventually be moved to Category 1 (permitted) or Category 3 (not permitted). During the evaluation period, the regulatory treatment of these substances varies, and compounding pharmacies face uncertainty regarding their use.

Category 3: Not Permitted for Compounding

Substances placed in Category 3 have been determined by the FDA to be inappropriate for compounding. Reasons for Category 3 designation include:

• Inadequate safety data
• Significant safety concerns
• Availability of an FDA-approved alternative
• Insufficient characterization of the substance
• Lack of a demonstrated clinical need for compounding

Impact on Peptide Availability

The Category system has directly affected the availability of numerous peptides through compounding pharmacies. Peptides that were previously widely compounded may become unavailable if classified as Category 3, or their status may remain uncertain while in Category 2. This has created supply disruptions and driven some patients and practitioners to seek alternative sources.

The classification of specific peptides is subject to change as the FDA completes its review process. Stakeholders can submit nominations and comments during the review.

Quality Considerations for Compounded Peptides

What to Look For

When evaluating compounded peptides, several quality indicators are important:

• Facility type: 503B outsourcing facilities offer stronger quality assurance through cGMP compliance and FDA oversight
• Third-party testing: Reputable compounding pharmacies provide Certificates of Analysis for their products, including HPLC purity, mass spectrometry identity confirmation, endotoxin testing, and sterility testing
• Beyond-use dating (BUD): Compounded preparations have assigned beyond-use dates based on stability data. These are typically shorter than commercial product expiration dates
• Storage requirements: Proper cold-chain handling for peptide preparations
• Pharmacist consultation: Access to pharmacist consultation regarding reconstitution, dosing, and storage

Quality Risks

Compounded peptides carry quality risks that are less prevalent with FDA-approved products:

• Potency variability: Without the rigorous batch-to-batch consistency requirements of commercial manufacturing, compounded products may show greater dose variability
• Sterility assurance: Sterile compounding is technically demanding. Facilities with inadequate environmental controls or techniques may produce contaminated products
• Stability data limitations: Commercial products have extensive stability data from formal studies. Compounded preparations may have limited stability testing supporting their beyond-use dates
• Raw material sourcing: The quality of the bulk peptide API depends on the supplier. Not all API suppliers maintain equivalent quality standards. See Purity and Testing

The GLP-1 Agonist Situation

The compounding of Semaglutide and Tirzepatide has become a focal point of regulatory attention. During periods when these products were on the FDA Drug Shortage List, compounding pharmacies were permitted to compound copies of these commercially available drugs — an exception to the general rule that compounders cannot produce copies of commercially available products.

This situation has created several dynamics:

• Price competition: Compounded semaglutide and tirzepatide are typically available at a fraction of the brand-name cost
• Regulatory uncertainty: As supply shortages resolve, the FDA may restrict or prohibit compounding of these drugs
• Quality variation: The quality of compounded GLP-1 agonists varies widely across pharmacies. Some 503B facilities produce pharmaceutical-grade products; others may have quality concerns
• Salt form considerations: Compounding pharmacies often use semaglutide sodium salt rather than the semaglutide base used in the branded product. Whether this distinction is clinically meaningful has been debated

Choosing a Compounding Pharmacy

For those working with compounded peptides, several factors inform pharmacy selection:

• Verify facility type and licensing: Confirm whether the pharmacy operates under 503A or 503B regulations. Check state pharmacy board registration
• Request COAs: Reputable pharmacies provide batch-specific Certificates of Analysis. Review these for completeness (see Reading a Certificate of Analysis)
• Ask about API sourcing: Where does the pharmacy obtain its bulk peptide ingredients? FDA-registered API suppliers are preferred
• Check accreditation: Voluntary accreditation through organizations like PCAB (Pharmacy Compounding Accreditation Board) indicates commitment to quality standards
• Prescription requirement: A valid prescription from a licensed healthcare provider should be required for any compounded peptide intended for human use

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical, legal, or pharmaceutical advice. Compounding regulations are subject to change, and readers should verify current requirements with appropriate regulatory authorities. Consult a qualified healthcare professional and licensed pharmacist for guidance on compounded medications.